NetworkNewsBreaks – Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) Secures $16M Grant from CIRM toward Phase 3 Clinical Trial of NurOwn® in ALS
Shares of Brainstorm Cell Therapeutics (NASDAQ: BCLI) are up more than 8% this morning after the company said it has been awarded a grant of $16 million by the California Institute for Regenerative Medicine (CIRM) to support the pivotal phase 3 study of NurOwn® for the treatment of amyotrophic lateral sclerosis (ALS). This grant signifies an endorsement from CIRM of the company’s approach to treat ALS using adult stem cells. The phase 3 clinical trial investigating NurOwn in ALS is expected to enroll approximately 200 patients and will be measured by the ALSFR-S score responder analysis. "This substantial award provides…